JP2012506699A - アフリカウマ病ウイルスに対するワクチン - Google Patents

アフリカウマ病ウイルスに対するワクチン Download PDF

Info

Publication number
JP2012506699A
JP2012506699A JP2011533331A JP2011533331A JP2012506699A JP 2012506699 A JP2012506699 A JP 2012506699A JP 2011533331 A JP2011533331 A JP 2011533331A JP 2011533331 A JP2011533331 A JP 2011533331A JP 2012506699 A JP2012506699 A JP 2012506699A
Authority
JP
Japan
Prior art keywords
ahsv
seq
vector
sequence
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011533331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506699A5 (https=
Inventor
ジュール マールテン ミンク
ジャン クリストフ オードネ
アラン ジョン ガスリー
ナイジェル ジェイムズ マクラクラン
ジャンシェン ヤオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012506699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of JP2012506699A publication Critical patent/JP2012506699A/ja
Publication of JP2012506699A5 publication Critical patent/JP2012506699A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011533331A 2008-10-24 2009-10-22 アフリカウマ病ウイルスに対するワクチン Pending JP2012506699A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US61/108,075 2008-10-24
US16351709P 2009-03-26 2009-03-26
US61/163,517 2009-03-26
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (2)

Publication Number Publication Date
JP2012506699A true JP2012506699A (ja) 2012-03-22
JP2012506699A5 JP2012506699A5 (https=) 2012-11-08

Family

ID=41818403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533331A Pending JP2012506699A (ja) 2008-10-24 2009-10-22 アフリカウマ病ウイルスに対するワクチン

Country Status (19)

Country Link
US (3) US8168200B2 (https=)
EP (1) EP2358742B1 (https=)
JP (1) JP2012506699A (https=)
KR (1) KR101719005B1 (https=)
CN (1) CN102245627A (https=)
AP (1) AP3334A (https=)
AR (1) AR074055A1 (https=)
AU (1) AU2009308331C1 (https=)
BR (2) BRPI0920622B1 (https=)
CA (1) CA2741333C (https=)
CL (1) CL2011000922A1 (https=)
EA (1) EA024111B1 (https=)
ES (1) ES2681693T3 (https=)
MX (1) MX2011004219A (https=)
NZ (2) NZ598605A (https=)
PL (1) PL2358742T3 (https=)
PT (1) PT2358742T (https=)
WO (1) WO2010048394A2 (https=)
ZA (1) ZA201103031B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598605A (en) * 2008-10-24 2014-04-30 Merial Ltd Vaccine against african horse sickness virus
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
AP2016009610A0 (en) * 2014-11-04 2016-12-31 Deltamune Pty Ltd Live attenuated african horsesickness virus
US11233998B2 (en) 2015-05-29 2022-01-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
CN111867637B (zh) * 2018-03-19 2024-05-03 勃林格殷格翰动物保健有限公司 新ehv插入位点ul43
US12581092B2 (en) 2022-03-03 2026-03-17 Qualcomm Incorporated Temporal initialization points for context-based arithmetic coding
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
EP4520797A1 (en) 2023-07-07 2025-03-12 Chukyo Yushi Co., Ltd. Dispersion
CN117737310B (zh) * 2024-01-26 2024-07-16 中国农业科学院北京畜牧兽医研究所 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505300A (ja) * 1998-03-03 2002-02-19 メリアル 組換え生ワクチンおよび補助剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
ZA976424B (en) * 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
NZ598605A (en) * 2008-10-24 2014-04-30 Merial Ltd Vaccine against african horse sickness virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505300A (ja) * 1998-03-03 2002-02-19 メリアル 組換え生ワクチンおよび補助剤

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6014011126; Ｖｉｒｏｌｏｇｙ Ｖｏｌ．２０２, 1994, ｐ．３４８-３５９ *
JPN6014011128; Ｊｏｕｒｎａｌ　ｏｆ　Ｇｅｎｅｒａｌ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７７, 1996, ｐ．２０５３-２０５７ *
JPN6014011130; Ｊｏｕｒｎａｌ　ｏｆ　Ｇｅｎｅｒａｌ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７７, 1996, ｐ．１２１１-１２２１ *
JPN6014011132; Ｖｉｒｏｌｏｇｙ Ｖｏｌ．２５７, 1999, ｐ．４４９-４５９ *
JPN6014011133; Ｊ．Ｖｅｔ．Ｍｅｄ．Ｓｃｉ． Ｖｏｌ．５６, 1994, ｐ．３２１-３２７ *
JPN6014011135; Ｄａｔａｂａｓｅ　ＧｅｎＢａｎｋ　［ｏｎｌｉｎｅ］ Ａｃｃｅｓｓｉｏｎ　Ｎｏ．ＥＵ０４６５７４, 20080725 *
JPN6014011136; Ｄａｔａｂａｓｅ　ＧｅｎＢａｎｋ　［ｏｎｌｉｎｅ］ Ａｃｃｅｓｓｉｏｎ　Ｎｏ．ＤＱ８６８７７３, 20080725 *
JPN6014011138; Ｖａｃｃｉｎｅ Ｖｏｌ．２５, 2007, ｐ．６７２-６７８ *
JPN6014011139; Ａｒｃｈｉｖｅｓ　ｏｆ　Ｖｉｒｏｌｏｇｙ　Ｓｕｐｐｌｅｍｅｎｔ Ｖｏｌ．０，　Ｎｏ．１４, 1998, ｐ．１７７-２０２　（ａｂｓｔｒａｃｔ），　ＢＩＯＳＩＳ　［ｏｎｌｉｎｅ］ *
JPN6015008507; Ｎ．　Ｊａｍｅｓ　ＭａｃＬａｃｈｌａｎ，　ｅｔ　ａｌ．: Ｖａｃｃｉｎｅ Ｖｏｌ．　２５，　Ｉｓｓｕｅ．　３０, 20070116, ＰＰ．　５５７７-５５８２ *

Also Published As

Publication number Publication date
AR074055A1 (es) 2010-12-22
AU2009308331C1 (en) 2015-07-09
AU2009308331B2 (en) 2014-08-21
ES2681693T3 (es) 2018-09-14
EA024111B1 (ru) 2016-08-31
EP2358742A2 (en) 2011-08-24
BR122019001455B1 (pt) 2021-01-19
CA2741333C (en) 2018-02-13
CL2011000922A1 (es) 2011-09-16
WO2010048394A3 (en) 2010-08-19
US8168200B2 (en) 2012-05-01
US20140120133A1 (en) 2014-05-01
ZA201103031B (en) 2014-03-26
CA2741333A1 (en) 2010-04-29
KR20110092281A (ko) 2011-08-17
BRPI0920622A8 (pt) 2019-02-05
WO2010048394A2 (en) 2010-04-29
MX2011004219A (es) 2011-09-22
KR101719005B1 (ko) 2017-03-22
EA201100674A1 (ru) 2011-12-30
CN102245627A (zh) 2011-11-16
AU2009308331A1 (en) 2010-04-29
BRPI0920622B1 (pt) 2019-11-12
US20120114691A1 (en) 2012-05-10
BRPI0920622A2 (pt) 2016-10-04
AP3334A (en) 2015-07-31
PL2358742T3 (pl) 2018-08-31
NZ598605A (en) 2014-04-30
AP2011005954A0 (en) 2011-10-31
EP2358742B1 (en) 2018-02-28
PT2358742T (pt) 2018-06-04
NZ592388A (en) 2012-03-30
US20100119546A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
CA2741333C (en) Vaccine against african horse sickness virus
US10006050B2 (en) Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
US10537632B2 (en) Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
US20100278862A1 (en) Nipah Virus Vaccines
CA2876196C (en) Reassortant btv vaccines
CN103957932B (zh) 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
AU2014218358B2 (en) Vaccine against african horse sickness virus
KR102934156B1 (ko) Fcv 재조합 백신 및 그의 용도
HK1157360B (en) Vaccine against african horse sickness virus
HK1157360A (en) Vaccine against african horse sickness virus
HK1219412A1 (zh) 对抗尼罗热病毒的疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151005